Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rofecoxib in Postoperative Dental Pain
NCT00092313Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2002
- Primary completion
- Sep 2002
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of rofecoxib in postoperative pain (3 arms), sponsored by Merck & Co. Primary endpoints: Pain Intensity and Pain Relief Scores at 6 hours, Patient Global Assessment of Response to Therapy at 6 hours and 1 more. Started Jun 2002; status: completed.
02
Drugs
rofecoxib
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT00092313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00092313.